Gilead Sciences (GILD)

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.

NICE recommends ViiV Healthcare's Apretude as the first injectable PrEP for HIV prevention, offering an alternative to daily oral medication.

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

In a financial landscape often fixated on consistent dividend payouts, United Therapeutics Corporation (NASDAQ: UTHR) stands out with a distinct capital allocation strategy. Contrary to market discussions about "dividend increases," the biotechnology firm has publicly stated it does not anticipate paying dividends in the immediate future. Instead, the company has

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 studies with stable weight outcomes.

Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combination therapy.

On CNBC's "Halftime Report Final Trades," Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences as his final trade.

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

The company is working toward a potential $5 billion sales peak for its partnered and unpartnered programs.

Gilead Sciences (GILD) presents a strong value investing case with a low P/E ratio, high profitability, and solid cash flow, suggesting the stock may be undervalued.

The company stated that under the settlements, no generic entry is expected for Biktarvy in the United States before April 1, 2036.

Gilead Sciences settled patent disputes with Lupin, Cipla, and Laurus, delaying U.S. generic entry of HIV drug Biktarvy until April 2036.

The appointment is effective immediately, replacing Hans Vestberg who has led Verizon since 2018.

The company is well known for its HIV treatment, Biktarvy. Biktarvy accounted for more than two-thirds of Gilead's HIV June-quarter sales.

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.

Both have crushed the market in 2025.

Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.

Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by Danish biotech giant Genmab A/S (NASDAQ: GMAB). The all-cash transaction, valued at approximately $8.0 billion, represents

As the clock ticks towards the September 30, 2025, funding deadline, the United States federal government finds itself perilously close to another shutdown. Congressional leaders remain deadlocked on a spending bill, with crucial negotiations underway to avert what would be the 15th partial federal government shutdown since 1981. This looming